0 0 0 0 0.00902959094865098 0.0175038076588338 0.000870322019147066 0.0261586161879895
Sign Up Today X
Thanks for submitting the form.
Stockreport

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]

Biogen Inc. (BIIB)  More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA ® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data supporting the Low Dose Regimen of SPINRAZA (12 mg), High Dose SPINRAZA was designed to deliver a higher concentration of drug through both the loading and maintenance dosing phases, to provide a new option in response to the ongoing needs of the community. The High Dose Regimen of SPINRAZA, which will be available in the coming weeks, enables an accelerated loading phase for those new to SPINRAZA treatment – with two 50 mg doses administered 14 days apart – followed by 28 mg maintena [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]

Biogen Inc.  (BIIB) 
More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA ® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data supporting the Low Dose Regimen of SPINRAZA (12 mg), High Dose SPINRAZA was designed to deliver a higher concentration of drug through both the loading and maintenance dosing phases, to provide a new option in response to the ongoing needs of the community. The High Dose Regimen of SPINRAZA, which will be available in the coming weeks, enables an accelerated loading phase for those new to SPINRAZA treatment – with two 50 mg doses administered 14 days apart – followed by 28 mg maintena [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS